2018

  • February 14, 2018 – Claret medical’s Sentinel® Cerebral Protection System emerging as U.S. standard of care for protecting the brain from risk of stroke during transcatheter aortic heart valve replacement.
    MORE

2017

  • October 23, 2017 – Claret Medical® developer of the Sentinel® Cerebral Protection System, the first FDA-cleared cerebral protection device for transcatheter aortic valve replacement (TAVR), today announced that it has closed on a Series C financing of $14.5 million
    MORE
  • September 18, 2017 – New study shows that Sentinel Cerebral Protection System significantly reduces stroke and mortality associated with transcatheter aortic valve replacement (TAVR)
    MORE
  • June 16, 2017 – Sentinel Cerebral Protection System used commercially by TAVR centers of excellence nationwide
    MORE
  • June 5, 2017 – Claret Medical receives FDA Clearance to market Sentinel Cerebral Protection System in the U.S.
    MORE
  • March 18, 2017 – New data presented at the American College of Cardiology by researchers from Ulm, Germany show that routine use of Sentinel in consecutive TAVR patients significantly reduces 7-day stroke by 86% and all-cause mortality or stroke by 82%.
    MORE
  • February 16, 2017 – The American Association of Neurological Surgeons (AANS) officially endorsed the Sentinel Cerebral Protection System
    MORE
  • February 27, 2017 – FDA advisory committee strongly supports granting De Novo application for the first cerebral protection system for transcatheter aortic valve replacement (TAVR)
    MORE

2016

  • November 1, 2016 – Results from U.S. pivotal IDE trial show that the Sentinel® Cerebral Protection System protects patients during transcatheter aortic valve replacement.
    MORE
  • September 20, 2016 – Claret Medical Marketing Submits Application to FDA for US Clearance of First Cerebral Protection System for Transcatheter Aortic Valve Replacement (TAVR)
    MORE
  • September 14, 2016 – Claret Medical Announces Sentinel Pivotal IDE Trial to be Featured in Late-Breaking Trial Session at Transcatheter Cardiovascular Therapeutics (TCT) Conference
    MORE

2015

  • October 14, 2015 – MISTRAL-C Trial Shows Definitive Neurocognitive Benefit for Patients Protected by Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement (TAVR)
    MORE

2014

  • October 6, 2014 – Claret Medical Announces First Patient Treated in U.S. SENTINEL Pivotal Trial
    MORE
  • September 13, 2014 – CLEAN-TAVI Trial Results Show That Claret Medical Cerebral Protection System Dramatically Reduces Brain Lesions and Neurological Events Following TAVR
    MORE
  • September 4, 2014 – Patient Enrollment Completed in Landmark CLEAN-TAVI Trial
    MORE
  • August 21, 2014 – Claret Medical Raises Up to $18 Million in Series B Financing to Advance the Field of Cerebral Protection
    MORE
  • February 18, 2014 – Claret Medical Announces IDE Approval for U.S. Pivotal Trial of Sentinel™ Cerebral Protection System
    MORE
  • January 27, 2014 – Claret Medical Announces CE Mark and European Launch of the Sentinel™ Cerebral Protection System
    MORE